INTRODUCTION
Cosmetic facial injections are one of the most common in-office procedures used to improve the signs of skin aging, including deep wrinkles and volume loss. Topical cosmetic skin products have also been shown to improve the appearance of fine and coarse lines/wrinkles, skin tone unevenness, and skin texture and radiance.1,2 There are a wide range of topical anti-aging skin products available, including sunscreens,2,3 antioxidants,4 retinoids,5,6 alpha hydroxy acids,7,8 and various growth-factor containing products.9,10 Facial rejuvenation products containing growth factors from a variety of sources, including plants, animals, and human tissues (including mesenchymal stem cells from adipose tissue, red deer umbilical cord lining, and human fibroblasts) have been developed.11,12 Although products may provide benefits through differing mechanisms, those containing human fibroblast-derived growth factors have shown considerable effects on stimulating dermal extracellular matrix (ECM) components considered key to the reversal of signs of skin aging.9,13
Numerous studies have demonstrated the clinical efficacy of specific skincare products for facial rejuvenation, but data on the effects of skincare following cosmetic facial injection procedures are limited.1,14-16 Therefore, we conducted an open-label study to assess the efficacy and tolerability of a novel medical-grade topical skincare regimen (including a growth factor-based product: TNS Advanced+) on female subjects with moderate to severe facial photodamage following pre-elected facial neuromodulator and hyaluronic acid (HA) dermal filler treatments. The physician-dispensed topical skincare regimen assessed in this study included basic skincare components (facial cleanser, moisturizer, and sunscreen; SkinMedica, Allergan, an AbbVie Company, Irvine, CA, USA), an HA-based rejuvenating hydrator, and an investigational antioxidant dual serum system in addition to TNS A+.
TNS A+, the novel hypoxic conditioned culture medium (HCCM)-based growth factor-based product used in the current study, was combined in a treatment regimen with a circadian-based antioxidant dual serum system (LumiVive® System [LVS]; SkinMedica; Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA), designed to protect against environment skin aggressors during the day and protect against metabolic oxidation to support cellular recovery at night,17,18 and an HA-based serum (HA5 Rejuvenating Hydrator; SkinMedica; Allergan Aesthetics, an AbbVie Company, Irvine, CA). The HA-based
Numerous studies have demonstrated the clinical efficacy of specific skincare products for facial rejuvenation, but data on the effects of skincare following cosmetic facial injection procedures are limited.1,14-16 Therefore, we conducted an open-label study to assess the efficacy and tolerability of a novel medical-grade topical skincare regimen (including a growth factor-based product: TNS Advanced+) on female subjects with moderate to severe facial photodamage following pre-elected facial neuromodulator and hyaluronic acid (HA) dermal filler treatments. The physician-dispensed topical skincare regimen assessed in this study included basic skincare components (facial cleanser, moisturizer, and sunscreen; SkinMedica, Allergan, an AbbVie Company, Irvine, CA, USA), an HA-based rejuvenating hydrator, and an investigational antioxidant dual serum system in addition to TNS A+.
TNS A+, the novel hypoxic conditioned culture medium (HCCM)-based growth factor-based product used in the current study, was combined in a treatment regimen with a circadian-based antioxidant dual serum system (LumiVive® System [LVS]; SkinMedica; Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA), designed to protect against environment skin aggressors during the day and protect against metabolic oxidation to support cellular recovery at night,17,18 and an HA-based serum (HA5 Rejuvenating Hydrator; SkinMedica; Allergan Aesthetics, an AbbVie Company, Irvine, CA). The HA-based
